Pemigatinib for Patients with Previously Treated, Locally Advanced or Metastatic Cholangiocarcinoma Harboring FGFR2 Fusions or Rearrangements: A Joint Analysis of the French PEMI-BIL and Italian PEMI-REAL Cohort Studies. Alessandro Parisi , Blandine Delaunay , Giada Pinterpe , Antoine Hollebecque , Jean Frederic Blanc , Mohamed Bouattour , Eric Assenat , Meher Ben Abdelghani , Matthieu Sarabi , Monica Niger , Caterina Vivaldi , Mario Mandala , Andrea Palloni , Maria Bensi , Silvio Ken Garattini , David Tougeron , Pierre Combe , Massimiliano Salati , Margherita Rimini , Chiara Alessandra Cella , Marco Tucci , Anna Diana , Elena Mori , Raffaella Longarini , Pascal Artru , Gael Roth , Ludovic Evesque , Agathe Vienne , Anthony Turpin , Sandrine Hiret , Vincent Bourgeois , Camille Herve , Rodolphe Paulon , Marion Stacoffe , David Malka , Cindy Neuzillet , Julien Edeline , Astrid Lievre , Rosine Guimbaud , Marie Christelle Pajiep Chapda , Lorenza Rimassa , Riccardo Giampieri , Juan Valle , Rossana Berardi , Nadim Fares European Journal of Cancer（2024）
关键词
BTC, Intrahepatic cholangiocarcinoma, FGFR2 fusions/rearrangements, Systemic treatment, Targeted therapy, Real-world data
AI 理解论文
溯源树
样例
